| Literature DB >> 35330652 |
Amar M Salam1, Imtiaz Salim1, Rasha Kaddoura2, Rajvir Singh2, Nidal Asaad1, Awad Al-Qahtani2, Jassim Al Suwaidi2, Hajar A AlBinali2.
Abstract
Background: The vast majority of literature on atrial fibrillation (AF) is based on studies from the developed world that mainly includes Caucasian patients. Data on AF in other ethnicities is very limited. The aim of this hospital-based study is to evaluate the effect of concomitant hypertension (HTN) on the characteristics and outcomes of Middle Eastern Arab and South Asian patients with AF in the state of Qatar. Materials and Methods andEntities:
Keywords: Atrial fibrillation; hypertension; registry
Year: 2022 PMID: 35330652 PMCID: PMC8939387 DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_33_21
Source DB: PubMed Journal: Heart Views ISSN: 1995-705X
Patients’ demographics, clinical characteristics and outcomes.
| Variable | AF + HTN | AF alone |
|
|---|---|---|---|
| 1483 (38.3) | 2367 (61.5) | ||
| Patient characteristics at admission | |||
| Age in year (mean±SD) | 63±12 | 52±16 | 0.001 |
| BMI (kg/m2) (mean±SD) | 32±7 | 29±10 | 0.001 |
| Female gender | 702 (47.3) | 715 (30.2) | 0.001 |
| Ethnicity (%) | |||
| Middle Eastern Arabs | 1191 (80.3) | 1666 (70.4) | |
| South Asians | 158 (10.7) | 390 (16.5) | |
| Others | 134 (9) | 311 (13.1) | 0.001 |
| Cardiovascular risk factors | |||
| Current smoker | 119 (8) | 358 (15.1) | 0.001 |
| Dyslipidemia | 214 (14.4) | 151 (6.4) | 0.001 |
| Diabetes mellitus | 754 (50.8) | 403 (17) | 0.001 |
| CKD | 127 (8.6) | 55 (2.3) | 0.001 |
| Dyslipidemia | 214 (14.4) | 151 (6.4) | 0.001 |
| Prior MI | 218 (14.7) | 199 (8.4) | 0.001 |
| Cardiac Diagnosis | |||
| ACS | 167 (11.3) | 122 (5.2) | 0.001 |
| Heart failure | 344 (23.2) | 351 (14.8) | 0.001 |
| VHD | 33 (2.2) | 133 (5.6) | 0.001 |
| RHD | 11 (0.7) | 86 (3.6) | 0.001 |
| Presenting symptom | |||
| Palpitation | 591 (39.9) | 1133 (47.9) | 0.001 |
| SOB | 483 (32.6) | 586 (24.8) | 0.001 |
| Chest pain | 250 (16.9) | 198 (8.4) | 0.001 |
| Dizziness | 89 (6) | 159 (6.7) | 0.38 |
| LVEF (mean±SD) | 44±14 | 45±13.5 | 0.25 |
| Hospital days (mean±SD) | |||
| CCU stay (days) | 2.8±2 | 2±2 | 0.001 |
| Total hospital stay (days) | 5±4 | 4±4 | 0.001 |
| In hospital outcome (%) | |||
| Death | 78 (5.3) | 82 (3.5) | 0.007 |
| Stroke | 11 (0.7) | 5 (0.2) | 0.01 |
ACS, acute coronary syndrome; AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass graft; CCU, coronary care unit; CKD, chronic kidney disease; HTN, hypertension; LVEF, left ventricular ejection fraction; MI, myocardial infarction; RHD, Rheumatic heart diseases; SD, standard deviation; SOB, shortness of breath; VHD, valvular heart diseases.
Medications used before presentation, during admission and at discharge.
| Medications in % | Before Admission | During Admission | At Discharge | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
| |||||||
| AF + HTN | AF no + HTN |
| AF + HTN | AF no + HTN |
| AF+HTN | AF no + HTN |
| |
| Aspirin | 612 (4.3) | 439 (18.5) | 0.001 | 885 (59.7) | 934 (39.5) | 0.001 | 9.26 (62.4) | 10.37 (43.8) | 0.001 |
| Warfarin | 17 (1.1) | 4 (2) | 0.04 | 279 (18.8) | 428 (18.1) | 0.57 | 525 (35.4) | 802 (33.9) | 0.33 |
| Clopidogrel | 75 (5.1) | 28 (1.2) | 0.001 | 127 (8.6) | 64 (2.7) | 0.001 | 94 (6.3) | 62 (2.6) | 0.001 |
| B blocker | 242 (16.3) | 129 (5.4) | 0.001 | 394 (26.6) | 501 (21.2) | 0.001 | 276 (18.6) | 382 (16.1) | 0.05 |
| CCB | 132 (8.9) | 33 (1.4) | 0.001 | 250 (16.9) | 136 (5.7) | 0.001 | 318 (21.4) | 151 (6.4) | 0.001 |
| Digoxin | 321 (21.6) | 466 (19.7) | 0.14 | 589 (39.7) | 1230 (52) | 0.001 | 537 (36.2) | 992 (41.9) | 0.001 |
| ACE inhibitors/ARBs | 263 (17.7) | 124 (5.2) | 0.001 | 587 (39.6) | 449 (19) | 0.001 | 693 (46.7) | 486 (20.5) | 0.001 |
| GPIIb/IIIa inhibitors | -- | -- | -- | 9 (0.6) | 7 (0.3) | 0.14 | -- | -- | -- |
| Unfractionated heparin | -- | -- | -- | 352 (23.7) | 701 (29.6) | 0.001 | -- | -- | -- |
| LMWH (enoxaparin) | 9 (0.6) | 2 (01) | 0.003 | 199 (13.4) | 245 (10.4) | 0.004 | 6 (0.4) | 10 (0.4) | 0.93 |
| Antiarrhythmics | 366 (24.7) | 502 (21.2) | 0.01 | 834 (56.2) | 1583 (66.9) | 0.001 | 700 (47.2) | 1164 (49.2) | 0.23 |
| Statins | -- | -- | -- | -- | -- | -- | 382 (25.8) | 231 (9.8) | 0.001 |
AF=Atrial Fibrillation; GP=glycoprotein; HTN=Hypertension; LMWH=low molecular weight heparin; CCB=calcium channel blockers; ACE=angiotension converting enzyme inhibitor, ARB=angiotensin receptor blocker.
Multivariate analysis of predictors of in-hospital mortality in patients with AF and hypertension.
| Variable | Adjusted OR | 95% CI |
|
|---|---|---|---|
| Age | 1.05 | 1.02-1.07 | 0.001 |
| Female gender | 0.88 | 0.54-1.45 | 0.63 |
| Current Smoking | 1.89 | 0.87-4.10 | 0.11 |
| Diabetes mellitus | 1.43 | 0.89-2.30 | 0.14 |
| MI | 1.36 | 0.77-2.39 | 0.29 |
| CKD | 1.69 | 0.87-3.26 | 0.12 |
Characteristics of patients with atrial fibrillation as reported in medical literature.
| Author/year | Patients studied | Number of patients | Mean age (SD) | Gender (M: F) | Co existing conditions | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||
| HTN (%) | DM (%) | CKD (%) | CAD (%) | CHF (%) | CVA (%) | Dyslipid (%) | VHD (%) | BMI (Kg/m2) | Smoking (%) | |||||
| Hurley | To asses HTN in pt >75yrs with AF in primary care setting, a secondary analysis of BAFTA study | 3059 | 82 (5) | 51:49 | 57.5 | 12.9 | NA | 35.1 h/o MI, 25.9 H/O angina | 25.8 | 12.3 | NA | 16.8 (RHD 6.4) | NA | 5.5 |
| Lee | Patients hospitalized with AF in Taiwan | 162,340 | 73.8 | 55.3: 44.7 | 14.8 | 16.3 | 1-1.6 | 21.4 | 23.8 | 15.2 | Na | 14.8 | NA | NA |
| Miyasaka | Patients with AF in Olmsted county, Minnesota | 4618 | 73.1 (14.4) | 51:49 | 80 | 18 | 17 | 38 | 9.7 | 9.5 | 37 | NA | 25.8 to 28 | NA |
| Nabauer | Patients with AF enrolled in AFNET registry, Germany | 9582 | 68.4 (11) | 60:40 | 69 | 21.6 | 11.6 | 28 | 36 | 6.4 | 46.2 | 36.3 (RHD 3.7) | NA | NA |
| Uchiyama | Analysis of J-TRACE registry | 2242 | 70.5 | 68.8: 31.2 | 57.7 | 17.2 | Na | 3.4 | 21.8 | 14.3 | 26.9 | ex | 32.8% with BMI >25 | 16.1 |
| Meinertz | Patients with AF enrolled in ATRIUM registry, Germany | 3667 | 72 (9) | 58:42 | 84 | 35 | 20 | 35 | 43 | 10.2 | Na | NA | 46% over wt, 32% obese | 5.5 |
| Steg | Patients with AF enrolled in Realise AF study | 10523 | 66.6 (12.1) | 56:44 | 72.2 | 21.3 | 3.9 | 32.3 | 45.8 | 14.1 | 46.3 | 26.7 | NA | 10.2 |
| Amerena | Ambulatory AF patients in RECORD AF- AP study | 2629 | 64 (13) | 60:40 | 58 | 18 | 6 | 19 | 25 | 9 | 37 | 23 | 25.5±4.9 | 13 |
| De Vos | Ambulatory AF patients in RECORD AF study | 2137 | 65.1 (12) | 53:47 | 70 | 15 | 6 | 19 | 20 | 8 | 46 | 17 | 28.2±5 | 14 |
| Olesen | Danish patients discharged from hospital with a diagnosis of AF | 132372 | 66 – 76 | 53:47 | 37 | 9 | 3.4 | NA | 17.7 | 14.1 | NA | ex | NA | NA |
AF=Atrial Fibrillation, BMI=Body Mass Index, CAD=Coronary Artery Disease, CHF=Congestive Heart Failure, CVA=Cerebrovascular Accident, DM=Diabetes Mellitus, ex=exclusion criteria, HTN=Hypertension, VHD=Valvular Heart Disease, NA=Data not available
Figure 1Medication use among patients with atrial fibrillation as reported in clinical studies from different geographic regions and its comparison with the two patient groups in the study